

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2348)

VOLUNTARY ANNOUNCEMENT

IN RELATION TO RECEIVING OF SUPPLY CONTRACT FOR HONG KONG MARKET

Received a supply contract of ENTIKAV[®] (Entecavir 0.5mg), an anti-virus medicinal product for chronic hepatitis B, manufactured by Suzhou Dawnrays Pharmaceutical Co., Ltd., a wholly owned subsidiary of the Company, and marketed and sold by GlaxoSmithKline Limited, for Hong Kong market.

This announcement is made by Dawnrays Pharmaceutical (Holdings) Limited (the “Company”) on a voluntary basis to keep shareholders and potential investors informed of the latest development of the Company.

The board of directors (the “Board”) of the Company is pleased to announce that ENTIKAV[®] (Entecavir 0.5mg) (“ENTIKAV[®]” or the “Product”), an anti-virus medicinal product for chronic hepatitis B manufactured by the Company’s wholly owned subsidiary Suzhou Dawnrays Pharmaceutical Co., Ltd. (“Suzhou Dawnrays Pharma”) (collectively referred to as the “Group”), is marketed and sold by GlaxoSmithKline Limited (“GSK”) in Hong Kong and Macau. Recently, GSK was awarded a supply contract (the “Contract”) for Hong Kong market. The Contract stipulated to begin supply of the Product in the second half of 2014.

ENTIKAV[®] is manufactured by Suzhou Dawnrays Pharma, after a large number of audits on quality and production management for the Product, GSK signed an agreement in 2012 for marketing and sales of ENTIKAV[®] in Hong Kong and Macau and then commenced related work. This time GSK successfully secured contract to supply ENTIKAV[®] for Hong Kong medical market, the Board believes that the Contract brings a good opportunity to the Group’s various finished products to enter other highly regulated markets and it will also increase the Group’s profitability.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 7 May 2014

As at the date of this announcement, the Board comprises seven Directors, of whom three are Executive Directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Li Tung Ming; one is Non-executive Director, Mr. Leung Hong Man; three are Independent Non-executive Directors, namely Mr. Pan Xue Tian, Mr. Choi Tat Ying Jacky and Mr. Lo Tung Sing Tony.

** For identification purpose only*